Intellia Therapeutics, Inc.NTLA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · intelliatx.com
Intellia Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-based therapies, with in vivo programs targeting hereditary angioedema and transthyretin amyloidosis and ex vivo programs in engineered cell therapy.
Key ratios
FCF / Sales
-586.0%TTM
2025
-585.0%2024
-612.8%2023
-1124.9%
ROA
-30.1%TTM
2025
-27.1%2024
-26.8%2023
-22.8%
ROE
-55.4%TTM
2025
-53.5%2024
-54.0%2023
-42.1%
Revenue growth
12.6%TTM
2025
16.9%2024
59.6%2023
-30.4%
Track NTLA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer